43:, disseminated (usually fatal) BCG infection, arthritis, and lymph node abscesses. Four deaths were registered in the official adverse event register, and while in only two cases a clear causal link was considered to be in place, two other cases were diagnosed with a disease that in scientific peer-reviewed articles (case descriptions) have been mistakenly first made, and afterward have been noticed to be disseminated BCG infections. One death with a causal link considered established by the adverse event monitoring agency was vaccinated with pre-August 2002 vaccine (Evans), while the three other registered deaths were with the new post-August 2002 vaccine (BCG vaccine SSI).
77:
authorization, the vaccine was offered and recommended to all
Finnish newborns (circa 55,000–60,000 per year), and parents were not told the vaccine had no marketing authorization, as required by Finnish and European Union legislation. The vaccine was injected into the thigh of newborns, despite clear manufacturer instructions that it should be administered to the upper arm, and despite the manufacturer's warning that injecting into a lower limb was associated with a greater number of adverse effects.
55:, National Research and Development Centre for Welfare and Health (STAKES), the Health Department, etc. In practice, however, almost everything connected to vaccines is done with the National Public Health Institute. The NPHI also does significant research funded by outside sources—circa 40% of funding is external, and the policy is to get as much outside funding as possible. Among the biggest funders has been the vaccine giant
98:
was prepared to let the vaccine be administered to all newborns until the beginning of 2008, mass inoculations were discontinued on 1 September 2006 after a draft report by the
Finnish Lung Health Association (Filha ry), which clearly stated that the vaccine does more harm than good for that specific
85:
Severe adverse effects were noticed in the media already in the spring of 2003, and on 27 May 2003, a grandmother also working in the medical trade called for the discontinuation of vaccinations. However, these continued as before, and representatives from the
National Public Health Institute of
86:
Finland as well an expert group set by NPHI responded on 3 June 2003 that there was no need to change the recommendation concerning vaccinations. In fact, already in
December 2002 a decision had been made to actively move towards vaccinating only those newborns at special risk for tuberculosis.
76:
In August 2002, the BCG vaccine used in
Finland was discontinued by the manufacturer after factory inspectors were dissatisfied with the manufacturing process. Finland switched to a Danish-strain BCG vaccine that did not have marketing authorization in Finland. Despite a lack of marketing
67:
In the 1970s, there was a similar outbreak of BCG osteitis osteomyelitis in Sweden and
Finland, when a Swedish-Danish BCG vaccine strain was used. To resolve the issue, Sweden discontinued mass BCG vaccinations to newborns, and Finland switched to a different strain.
107:
On 4 January 2009, the vaccine information association
Rokotusinfo ry issued a media release saying that it had requested the police to investigate whether crimes had been committed relating to the use of the BCG vaccine.
35:
BCG, and in BCG disease, the bacterium causes a disease in vaccinated persons. Between 2000 and 2006, several hundred children in
Finland had serious adverse reactions from the vaccine, including
51:
Officially, vaccination policy in
Finland is divided among many governmental organizations, such as the National Agency for Medicines, National Public Health Institute, the
196:
151:
95:
52:
279:
324:
329:
260:
NPHI of
Finland: Finland switches rapidly from universal tuberculosis vaccination of all newborns to targeted risk group vaccination.
314:
309:
304:
299:
294:
289:
284:
259:
125:
193:
25:
158:
223:
Rokotusinfo ry - HS Mielipide 3.6.2003: Ammattilaiset vastaavat Kansanterveyslaitokselle osoitettuun kritiikkiin
319:
274:
222:
186:
244:
233:
200:
190:
56:
211:
268:
40:
194:
http://www.ktl.fi/attachments/english/organization/ktlannual_report_2005_nettiin.pdf
129:
212:
Rokotusinfo ry - Kritiikkiä Calmette-rokotteen haittojen käsittelyä kohtaan
36:
152:"GOOD RESEARCH PRACTICE IN THE NATIONAL PUBLIC HEALTH INSTITUTE (2006)"
28:
16:
Adverse effect of the Bacillus Calmette-Guérin vaccine
183:
245:Rokotusinfo ry, media release, 4 January 2009
8:
96:National Public Health Institute of Finland
53:National Authority for Medicolegal Affairs
117:
182:KTL (NPHI) Annual Reports 2003-2005,
7:
81:Publicity and continued vaccinations
14:
31:. The vaccine contains living
1:
47:Vaccination policy in Finland
24:is an adverse effect of the
280:Health disasters in Finland
346:
325:2000s disasters in Finland
330:2000 disasters in Finland
72:Beginning of the outbreak
26:Bacillus Calmette-Guérin
189:23 October 2006 at the
126:"KTL - sivua ei löydy!"
59:between 2003 and 2005.
315:2006 disease outbreaks
310:2005 disease outbreaks
305:2004 disease outbreaks
300:2003 disease outbreaks
295:2002 disease outbreaks
290:2001 disease outbreaks
285:2000 disease outbreaks
199:15 July 2006 at the
132:on 25 September 2006
90:Resolving the issue
33:Mycobacterium bovis
184:http://www.ktl.fi
337:
247:
242:
236:
231:
225:
220:
214:
209:
203:
180:
174:
173:
171:
169:
163:
157:. Archived from
156:
148:
142:
141:
139:
137:
128:. Archived from
122:
345:
344:
340:
339:
338:
336:
335:
334:
320:2006 in Finland
275:2000 in Finland
265:
264:
256:
254:Further reading
251:
250:
243:
239:
232:
228:
221:
217:
210:
206:
201:Wayback Machine
191:Wayback Machine
181:
177:
167:
165:
161:
154:
150:
149:
145:
135:
133:
124:
123:
119:
114:
105:
92:
83:
74:
65:
57:GlaxoSmithKline
49:
17:
12:
11:
5:
343:
341:
333:
332:
327:
322:
317:
312:
307:
302:
297:
292:
287:
282:
277:
267:
266:
263:
262:
255:
252:
249:
248:
237:
234:Rokotusinfo ry
226:
215:
204:
175:
164:on 7 June 2011
143:
116:
115:
113:
110:
104:
101:
91:
88:
82:
79:
73:
70:
64:
61:
48:
45:
15:
13:
10:
9:
6:
4:
3:
2:
342:
331:
328:
326:
323:
321:
318:
316:
313:
311:
308:
306:
303:
301:
298:
296:
293:
291:
288:
286:
283:
281:
278:
276:
273:
272:
270:
261:
258:
257:
253:
246:
241:
238:
235:
230:
227:
224:
219:
216:
213:
208:
205:
202:
198:
195:
192:
188:
185:
179:
176:
160:
153:
147:
144:
131:
127:
121:
118:
111:
109:
102:
100:
97:
89:
87:
80:
78:
71:
69:
62:
60:
58:
54:
46:
44:
42:
41:osteomyelitis
38:
34:
30:
27:
23:
19:
240:
229:
218:
207:
178:
166:. Retrieved
159:the original
146:
134:. Retrieved
130:the original
120:
106:
99:population.
93:
84:
75:
66:
50:
32:
21:
20:
18:
22:BCG disease
269:Categories
168:22 October
136:22 October
112:References
94:While the
103:Aftermath
197:Archived
187:Archived
37:osteitis
63:History
29:vaccine
162:(PDF)
155:(PDF)
170:2006
138:2006
39:and
271::
172:.
140:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.